Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples